NCT07376603 is a clinical trial of IMRT along in Nasopharyngeal Cancinoma (NPC), sponsored by Qiaojuan Guo.

Who is sponsoring NCT07376603?

NCT07376603 is sponsored by Qiaojuan Guo.

What drugs are being tested in NCT07376603?

Interventions in NCT07376603: IMRT along.

What condition does NCT07376603 study?

NCT07376603 studies Nasopharyngeal Cancinoma (NPC), Intensity-modulated Radiotherapy, Stage IB.

Is NCT07376603 still recruiting?

NCT07376603 is currently recruiting now. Last updated 29 January 2026.

Last reviewed 2026-01-29 · How we verify

NCT07376603

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features

Recruiting now Last updated 29 January 2026

What this trial tests

trial testing IMRT along in Nasopharyngeal Cancinoma (NPC) in 169 participants. Currently enrolling.

Timeline

12 January 2026

Primary endpoint
31 December 2030

31 December 2030

Quick facts

Lead sponsor	Qiaojuan Guo
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	169
Start date	12 January 2026
Primary completion	31 December 2030
Estimated completion	31 December 2030
Sites	1 location across China

Drugs / interventions tested

IMRT along

Conditions studied

Nasopharyngeal Cancinoma (NPC) — all drugs for Nasopharyngeal Cancinoma (NPC) →
Intensity-modulated Radiotherapy — all drugs for Intensity-modulated Radiotherapy →
Stage IB — all drugs for Stage IB →

Sponsor

Qiaojuan Guo

Who can join

Adults 18 to 70, any sex, with Nasopharyngeal Cancinoma (NPC) or Intensity-modulated Radiotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This observational study aims to evaluate the efficacy and safety of intensity-modulated radiotherapy (IMRT) alone in patients with stage IB nasopharyngeal carcinoma (NPC) without high-risk features. The primary objective is to determine the therapeutic effectiveness of this approach

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Nasopharyngeal Cancinoma (NPC)

Currently open trials in the same condition.

NCT07362979 — Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal C · Phase 2 · recruiting
NCT07496190 — Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy · Phase 2 · recruiting
NCT07325539 — LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC · Phase 2 · recruiting
NCT07311772 — Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid · Phase 3 · recruiting
NCT07232680 — Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon Chemoradiotherapy · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07376603 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qiaojuan Guo
Last refreshed: 29 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07376603.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing